Dupilumab Phase IIb shows improvement in patient-reported outcomes for dermatitis

23 February 2015

A Phase IIb study of dupilumab, from French drug major Sanofi (Euronext: SAN) and US biotech firm Regeneron (Nasdaq: REGN), has shown that the drug improved patient-reported outcomes in moderate-to-severe atopic dermatitis.

It is currently in Phase III for the indication, and will enter Phase III for asthma in the first half of this year.

At 16 weeks, dupilumab significantly reduced itch on the numeric rating scale in 20% to 54% of patients versus 8.2% in placebo group, along with improvements in sleep on items of scoring atopic dermatitis and patient oriented eczema measures. It also significantly reduced symptoms of depression and anxiety on the hospital anxiety and depression scale.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK